Role of plasminogen activator inhibitor type 1 in tumour angiogenesis;Rôle de l'inhibiteur des activateurs de plasminogène de type 1 dans l'angiogénèse tumorale

Therapie

Volumn 56, Issue 5, 2001, Pages 465-472

  Bajou, K ^a   Devy, L ^a   Masson, V ^a   Albert, V ^a   Frankenne, F ^a   Noel, A ^a   Foidart, J M ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Angiogenesis; Migration; Proteolysis; Serine protease; Tumour invasion

Indexed keywords

PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERINE PROTEINASE;

CANCER GROWTH; CONFERENCE PAPER; EXTRACELLULAR MATRIX; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; PROTEIN DEGRADATION; REGULATORY MECHANISM; TUMOR VASCULARIZATION;

CAPILLARIES; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PLASMINOGEN ACTIVATOR INHIBITOR 1;

EID: 0035668838     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (60)

1. Emerging roles for proteinases in cancer
2. Plasminogen activators, tissue degradation, and cancer
3. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation
4. Biology and biochemistry of proteinases in tumor invasion
5. Tumor angiogenesis: A possible control point in tumor growth
6. Regulation of cancer invasion and vascularization by plasminogen activator inhibitor-1
7. The urokinase-type plasminogen activator system in cancer metastasis: A review
8. Proteolytic control of growth factor availability
9. Development and disease in proteinase-deficient mice: Role of the plasminogen, matrix metalloproteinase and coagulation system
10. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation
11. The activation of prourokinase by plasma kallikrein and its inactivation by thrombin
12. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA)
13. On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture
14. Binding and activation of plasminogen on the platelet surface
15. Binding of plasminogen to cultured human endothelial cells
16. Further characterization of the cellular plasminogen binding site: Evidence that plasminogen 2 and lipoprotein a compete for the same site
17. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer
18. Prognostic significance of urokinase-type plasminogen activator expression in squamous cell carcinomas of the esophagus
19. Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma
20. Upregulation of urokinase receptor expression on migrating endothelial cells
21. Migrating vascular smooth muscle cells polarize cell surface urokinase receptors after injury in vitro
22. Role of urokinase type plasminogen activator (u-PA) in corneal epithelial migration
23. Inhibition of urokinase-type plasminogen activator by antibodies: The effect on dissemination of a human tumor in the nude mouse
24. Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B16 cells transfected with human urokinase sense and antisense genes
25. The urokinase receptor. A cell surface, regulated chemokine
26. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration
27. Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy
28. Endothelial plasminogen activator inhibitor (PAI): A new member of the Serpin gene family
29. The organization of the human-plasminogen-activator-inhibitor-1 gene. Implications on the evolution of the serine-protease inhibitor family
30. Urokinase-type plasminogen activator (uPA) and its receptor (CD87): A new target in tumor invasion and metastasis
31. A model of the reactive form of plasminogen activator inhibitor-1
32. Biosynthesis and apical localization of the urokinase receptor in polarized MDCK epithelial cells
33. Molecular interaction involving urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor, plasminogen activator inhibitor-1 (PAI-1), as new targets for tumour therapy
34. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes
35. The PAI-1/vitronectin interaction: Two cats in a bag?
36. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants
37. Regulation of cell adhesion by PAI-1
38. Molecular advances in plasminogen activator inhibitor 1 interaction with thrombin and tissue-type plasminogen activator
39. Plasminogen activator inhibitor is associated with the extracellular matrix of cultured bovine smooth muscle cells
40. Melanoma cell migration on vitronectin: Regulation by components of the plasminogen activation system
41. Identification of the urokinase receptor as an adhesion receptor for vitronectin
42. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?
43. The urokinase receptor is a major vitronectin-binding protein on endothelial cells
44. Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1
45. alpha-2 macroglobulin receptor/Ldl receptor-related protein(Lrp)-dependent internalization of the urokinase receptor
46. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin
47. The plasminogen-plasminogen activator (PA) system in neuroblastoma: Role of PA inhibitor-1 in metastasis
48. The plasminogen activation system in human colon cancer: Messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma
49. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells
50. The urokinase plasminogen activator system as a target for prognostic studies in breast cancer
51. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue
52. Cancer and thrombosis: From Phlegmasia alba dolens to transgenic mice
53. Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma
54. The antibody to plasminogen activator inhibitor-1 suppresses pulmonary metastases of human fibrosarcoma in athymic mice
55. Absence of host plasminogen activator inhibitor I prevents cancer invasion and vascularization
56. Growth of microvessels in serum-free matrix culture of rat aorta. A quantitative assay of angiogenesis in vitro
57. Plasminogen activators augment endothelial cell organization in vitro by two distinct pathways
58. Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation
59. Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene
60. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin: Implications for anti-angiogenic strategies